Former Chief Medical Officer and Assistant Secretary for Health Affairs of the U.S. Department of Homeland Security, Dr. Jeff...
October 01 2020 - 8:00AM
via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the
“Company”) (Nasdaq: ADTX), a life sciences company developing
biotechnologies specifically focused on improving the health of the
immune system through immune monitoring and reprogramming, today
announced that it has appointed Dr. Jeffrey Runge, MD, FACEP, to
the Company’s Board of Directors effective as of July 16, 2020. Dr.
Runge will be an independent director in accordance with the
applicable rules of the Nasdaq Stock Market LLC.
Dr. Runge has over 35-years of clinical,
research, leadership, and administrative experience, as well as
being a board-certified physician in emergency medicine. Most
notably, from 2001-2005 Dr. Runge served as the U.S. Department of
Homeland Security’s (DHS) first Chief Medical Officer and Assistant
Secretary for Health Affairs, where he led the reorganization of
biodefense operations into a new Office of Health Affairs.
Amro Albanna, Co-Founder and Chief Executive
Officer of Aditxt, stated, “Aditxt is pleased to welcome Dr.
Jeffrey Runge as our newest board director. Jeff has a long history
of innovation, leadership, and success developing impactful
strategies, programs and policies in the public, institutional
healthcare, and private sectors. His expertise spans the fields of
homeland defense, threat mitigation and prevention, medical
preparedness, regulatory framework, and medical services delivery.
His experience as a creator and developer of regulation as Chief
Medical Officer of a newly formed governmental agency will provide
tremendous guidance and assistance to Aditxt as we embark on the
next stages of our growth.”
Prior to his tenure at DHS, Dr. Runge served as
the Administrator of the National Highway Traffic Safety
Administration (NHTSA) at the U.S. Department of
Transportation from 2001 – 2005. Under his leadership as head of
these two government agencies Dr. Runge was responsible for over
1000 employees and contractors. Until 2001 he practiced and taught
in North Carolina’s busiest emergency department and trauma center,
while performing research in injury prevention, trauma care, and
emergency service delivery. Dr. Runge is a 1977 graduate of the
University of the South, Sewanee, TN, and received his medical
degree from the Medical University of South Carolina in 1981. He
has been honored by both institutions in recent years as a
Distinguished Alumnus. Dr. Runge is board certified in Emergency
Medicine and has published over 60 articles in the medical
literature in the fields of emergency medicine, traffic injury
control and medical preparedness. He has testified 25 times before
the United States Congress and various state legislatures on
highway safety and homeland security issues.
About Aditx Therapeutics
Aditxt is developing technologies specifically
focused on improving the health of the immune system through immune
monitoring and reprogramming. The immune monitoring technology is
designed to provide a personalized comprehensive profile of the
immune system. The immune reprogramming technology is currently at
the pre-clinical stage and is designed to retrain the immune system
to induce tolerance with an objective of addressing rejection of
transplanted organs, autoimmune diseases, and allergies. For more
information, please visit: www.aditxt.com
Forward-Looking Statements
Certain statements in this press release
constitute “forward-looking statements” within the meaning of the
federal securities laws. Forward looking statements include
statements regarding the Company’s intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, the Company’s ongoing and planned product
development; the Company’s intellectual property position; the
Company’s ability to develop commercial functions; expectations
regarding product launch and revenue; the Company’s results of
operations, cash needs, spending, financial condition, liquidity,
prospects, growth and strategies; the industry in which the Company
operates; and the trends that may affect the industry or the
Company. Forward-looking statements are not guarantees of future
performance and actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors, as well as those risks more fully
discussed in the section entitled “Risk Factors” in the Company’s
prospectus, dated September 1, 2020, that was filed with the
Securities and Exchange Commission under File No. 333-248491, as
well as discussions of potential risks, uncertainties, and other
important factors in the Company’s subsequent filings with the
Securities and Exchange Commission. All such statements speak only
as of the date made, and the Company undertakes no obligation to
update or revise publicly any forward-looking statements, whether
as a result of new information, future events or otherwise.
Investor Relations:PCG Advisory Jeff RamsonChief
Executive OfficerIR@aditxt.com 646-762-4518www.aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Sep 2023 to Sep 2024